Every article, presentation, spotlight, and news item we've tagged to Mental and Cognitive Health.
Showing 25–48 of 128
Chronic acid accumulation from aging and stress depletes the body's buffering capacity, disrupting communication between physiological systems and driving frailty through impaired energy metabolism. This acid-base dysregulation mechanism unifies existing frailty models and identifies diet, exercise, and buffering strategies as therapeutic targets.
Type 2 diabetes with worsening diabetic retinopathy correlates with significantly elevated dementia risk, with severe eye disease conferring 58% higher risk for any dementia and more than double the risk for vascular dementia. The retina serves as a measurable window into microvascular integrity throughout the body, including the cerebral vasculature, making routine eye screening a potential early intervention point for cognitive decline.
Alzheon's ALZ-801 demonstrated sustained reductions in plasma phosphorylated tau 217 across Phase 2 and Phase 3 trials, with biomarker changes correlating to cognitive preservation and protection against hippocampal volume loss in early Alzheimer's disease. These results support the compound's mechanism of inhibiting neurotoxic amyloid oligomer formation at disease stages where intervention may be most effective.
High-impact chronic pain is associated with subjective cognitive decline, with age acting as a moderating factor. This relationship has implications for understanding how persistent pain states interact with cognitive aging and longevity outcomes.
Machine learning models trained on routine clinic data predict individual rates of cognitive and functional decline in Alzheimer's disease and mild cognitive impairment with greater accuracy than population averages. Early identification of specific functional vulnerabilities—such as difficulty with finances or meal preparation—enables targeted interventions before independence is lost.
Cognito Therapeutics has committed to eliminating the term 'dementia' from all communications in partnership with the Initiative to Change the D-Word, prioritizing patient-centered language that reduces stigma and supports earlier recognition of cognitive decline. This linguistic shift reflects a broader movement toward precision in how cognitive pathology is discussed and treated.
Individuals with more problematic people in their close social networks exhibit accelerated biological aging, with each additional "hassler" associated with a 1.5% faster aging pace and approximately 9.5 months of additional biological age. This effect persists after controlling for demographic, occupational, and health factors, establishing social stress as a measurable driver of epigenetic aging.
Researchers at Oregon Health & Science University are developing a retinal screening tool using fluorescent eye drops to detect amyloid proteins associated with Alzheimer's disease before memory loss occurs. This approach could enable population-level screening in routine ophthalmology clinics, identifying individuals at risk when emerging treatments are most effective.
A 75-year-old carrier of a dominant Alzheimer's mutation remained cognitively intact, suggesting that genetic predisposition does not determine disease expression. This case indicates that protective mechanisms—possibly involving heat shock proteins and cellular stress response—can override genetic risk, with implications for understanding preventive intervention strategies in neurodegeneration.
A longitudinal study found that 45% of older adults show cognitive improvement over a decade, with positive age-related beliefs associated with better outcomes. This challenges the assumption that cognitive decline is inevitable with age and suggests mindset-dependent mechanisms may influence cognitive trajectory.
Stanford researchers created the first comprehensive atlas of lysosomal proteins across four major brain cell types, revealing cell-specific patterns that explain how waste accumulation contributes to Alzheimer's, Parkinson's, and other neurodegenerative diseases. This cellular-level mapping shifts neurodegeneration research toward early prevention rather than late-stage intervention, with direct implications for maintaining cognitive function across the lifespan.
The DAC Egypt Cohort is a longitudinal study designed to identify early biomarkers and risk factors for Alzheimer's disease in an understudied Egyptian population, addressing a critical gap in dementia research outside Western cohorts. Early detection and prevention strategies depend on understanding how disease processes vary across genetic and environmental contexts.
Life stressors correlate with loneliness in older adults, with family functioning and self-perceptions of aging serving as modifiable pathways that influence this relationship. Understanding these associations provides targets for intervention in a population at elevated risk for isolation-related health decline.
Severe infections carry independent dementia risk beyond what frailty and comorbidities explain, suggesting infection-related mechanisms directly contribute to cognitive decline. This identifies a modifiable pathway distinct from typical aging trajectories.
Natural disaster exposure in older adults correlates with reduced cognitive function, with effects significantly amplified in those who experienced adverse childhood events. This suggests cumulative stress across the lifespan shapes cognitive resilience in aging.
Both short and long sleep duration independently increase chronic disease risk in older adults, with sleep duration showing a dose-response relationship to multimorbidity. The effect operates through metabolic dysregulation, inflammatory pathways, and autonomic nervous system dysfunction rather than a single mechanism.
Bexorg has secured funding to validate TRPML1, a protein target for Parkinson's therapies, using preserved human brain tissue paired with AI-driven biomarker identification. This approach addresses a critical translational gap: the inability to confirm drug efficacy in human neural tissue, which has caused over 95% of CNS drug candidates to fail in clinical trials despite theoretical promise.
Dizziness and vestibular dysfunction emerge as measurable precursors to cognitive decline and dementia, suggesting that dysfunction in balance and spatial orientation systems may reflect broader neurological compromise before overt cognitive symptoms manifest. This finding repositions a common but often-overlooked symptom as a potential biomarker for early neurological risk.
Brain structural similarity patterns on MRI predict individual rates of cognitive decline better than chronological age alone, suggesting that neural architecture itself encodes aging trajectories. This offers a measurable biological marker for identifying cognitive vulnerability before clinical decline becomes apparent.
C2N Diagnostics and Codex Genetics are expanding access to PrecivityAD2, a blood test measuring amyloid biomarkers to assess Alzheimer's risk in asymptomatic or early-symptomatic individuals. Early detection via non-invasive biomarker assessment enables intervention before cognitive decline becomes clinically apparent, shifting Alzheimer's management from reactive to preventive.
Ageism and self-perceptions of aging cluster into distinct psychosocial profiles that correlate with cognitive performance and mental health outcomes in older adults. These profiles suggest that internalized attitudes toward aging—shaped by both cultural messaging and personal belief—measurably influence brain function and psychological resilience.
An audiovisual game-based educational program improved healthcare students' attitudes toward dementia, demonstrating that interactive learning methods can shift perception and potentially influence future clinical care quality. This has indirect relevance to longevity contexts where provider attitudes shape patient outcomes and engagement with cognitive health management.
SuperAgers—individuals over 80 with memory performance matching those decades younger—maintain roughly twice the neurogenic capacity of age-matched peers, driven by preserved epigenetic regulation that keeps regenerative neural programs accessible. This finding reframes cognitive aging from inevitable decline to a regulated, potentially modifiable biological process.
Annovis Bio is advancing buntanetap, an oral therapy targeting multiple neurotoxic proteins implicated in Alzheimer's disease, moving beyond the single-protein paradigm that has dominated the field. This multi-target approach addresses a fundamental gap between pathophysiological evidence and current therapeutic strategy, with Phase 3 data supporting both clinical benefit and biomarker improvement.
